Home » Expanded Access

Expanded Access for MDMA-Assisted Therapy 

An expanded access program allows pharmaceutical companies, in limited circumstances, to provide patients with an investigational medical product not yet approved by the U.S. Food and Drug Administration (FDA) for treatment outside of a clinical trial. The program is intended for patients with serious or life-threatening conditions when no comparable or satisfactory alternative therapy options are available and who are ineligible or unable to participate in ongoing clinical trials.  

MAPS PBC received FDA authorization to establish an expanded access program for MDMA-assisted therapy for up to 50 patients with post-traumatic stress disorder (PTSD) who met specific eligibility criteria. That program has been fully enrolled and is no longer accepting applications.  

We appreciate the urgent need for new and effective treatments for PTSD and are focused on pursuing FDA approval for MDMA-assisted therapy to help make it more widely available to people with PTSD.  

MAPS Public Benefit Corporation

Our Mission
Who We Are
Contact Us
Privacy Policy

Cookie Policy

3141 Stevens Creek Blvd #40547
San Jose, CA 95117

Therapy Education for Healthcare Providers

Our Commitment to Therapy Education


MAPS PBC is a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS). MAPS is a 501(c)(3) non-profit research and educational organization.

Stay Up-to-Date about the MDMA-AT Education Program

You have Successfully Subscribed!